Decreased Serotonin Levels and Serotonin‐Mediated Osteoblastic Inhibitory Signaling in Patients With Ankylosing Spondylitis. (13th October 2015)

• Record Type: Journal Article
• Authors: Klavdianou, Kalliopi; Liossis, Stamatis‐Nick; Papachristou, Dionysios J; Theocharis, Georgios; Sirinian, Chaido; Kottorou, Anastasia; Filippopoulou, Alexandra; Andonopoulos, Andrew P; Daoussis, Dimitrios
• Is Part Of: Journal of bone and mineral research. Volume 31:Number 3(2016:Mar.)
• Page Start: 630
• Page End: 639
• Publication Date: 2015-10-13
• Subjects: ANKYLOSING SPONDYLITIS -- SEROTONIN -- NEW BONE FORMATION -- OSTEOBLASTOGENESIS -- SPONDYLOARTHROPATHIES -- ANTI‐TNFα TREATMENT -- TNFα BLOCKER; Bones -- Metabolism -- Periodicals; Mineral metabolism -- Periodicals; 612.392
• DOI: 10.1002/jbmr.2724
• Languages: English
• ISSNs: 0884-0431

Abstract

ABSTRACT: Evidence suggests that serotonin is an inhibitor of bone formation. We aimed to assess: 1) serum serotonin levels in patients with ankylosing spondylitis (AS), a prototype bone‐forming disease, compared with patients with rheumatoid arthritis (RA) and healthy subjects; 2) the effect(s) of TNFα blockers on serum serotonin levels in patients with AS and RA; and 3) the effect(s) of serum of AS patients on serotonin signaling. Serum serotonin levels were measured in 47 patients with AS, 28 patients with RA, and 40 healthy subjects by radioimmunoassay; t test was used to assess differences between groups. The effect of serum on serotonin signaling was assessed using the human osteoblastic cell line Saos2, evaluating levels of phospho‐CREB by Western immunoblots. Serotonin serum levels were significantly lower in patients with AS compared with healthy subjects (mean ± SEM ng/mL 122.9 ± 11.6 versus 177.4 ± 24.58, p = 0.038) and patients with RA (mean ± SEM ng/mL 244.8 ± 37.5, p = 0.0004). Patients with AS receiving TNFα blockers had significantly lower serotonin levels compared with patients with AS not on such treatment (mean ± SEM ng/mL 95.8 ± 14.9 versus 149.2 ± 16.0, p = 0.019). Serotonin serum levels were inversely correlated with pCREB induction in osteoblast‐like Saos‐2 cells. Serotonin levels are low in patients with AS and decrease even further during anti‐TNFα treatment. Differences in serotonin levels are shown to have a functional impact on osteoblast‐like Saos‐2 cells. Therefore, serotonin may be involved in new bone formation in AS. © 2015 American Society for Bone and Mineral Research.